World Rabies Vaccine Market Report 2019-2024 - Purified Chick Embryo Cell Rabies Vaccine is Estimated to Contribute Large -

DUBLIN--()--The "Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to's offering.

In the developed markets, the cases of human rabies is less because of more pet friendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns.

Such factors raise the concerns regarding low protection against dog bites which raises the demand for rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Estimated to Contribute Large, Over the Forecast Period

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus.

Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive their importance and usage across hospitals and clinics.

North America is Estimated to Have Largest Share in the Global Market

According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies in 2015. In the past few years, the number of human deaths attributed to rabies in the United States has declined due to two major reasons, the first one is animal control and vaccination programs.

Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly, major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. A significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are AstraZeneca (MedImmune), GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, and Cadila Pharmaceuticals Ltd, among others.

Key Topics Covered


1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Growing Burden of Mortality due to Rabies

4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries

4.2.3 Growing Pet Management technological Advancements and Services

4.3 Market Restraints

4.3.1 Low Immunization Rates in Dogs

4.3.2 Lack of Awareness and Negligence by Government and Public

4.4 Porter's Five Force Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry


5.1 By Product Type

5.1.1 Baby Hamster Kidney (BHK)

5.1.2 Purified Chick Embryo Cell Rabies Vaccine

5.1.3 Vero Cell Rabies Vaccine

5.1.4 Other Product Types

5.2 By Vaccination Type

5.2.1 Pre-Exposure Vaccination (PEV)

5.2.2 Post-Exposure Prophylaxis (PEP)

5.3 By End User

5.3.1 Animals

5.3.2 Humans

5.4 Geography

5.4.1 North America United States Canada Mexico

5.4.2 Europe France Germany United Kingdom Italy Spain Rest of Europe

5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific

5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa

5.4.5 South America Brazil Argentina Rest of South America


6.1 Company Profiles

6.1.1 AstraZeneca (MedImmune)

6.1.2 Berna Biotech Ltd.

6.1.3 GlaxoSmithKline

6.1.4 Merck & Co. Inc.

6.1.5 Novartis AG

6.1.6 Pfizer Inc.

6.1.7 Sanofi Pasteur, Inc.

6.1.8 Zoetis Animal Healthcare

List Not Exhaustive...


For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900